Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ: ARQT )

14.72 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,484
Open 14.72
Bid (Size) 14.60 (14)
Ask (Size) 14.97 (4)
Prev. Close 14.72
Today's Range 14.72 - 14.72
52wk Range 6.990 - 17.75
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick?
A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing? 
Via Chartmill
Arcutis Announces Chief Financial Officer Transition
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+1.10%
+1.10%
1 Month
-13.97%
-13.97%
3 Month
+8.24%
+8.24%
6 Month
+75.03%
+75.03%
1 Year
+68.23%
+68.23%

More News

Read More
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews
Via Benzinga
Arcutis and Padagis Agree to Stay Patent Lawsuit
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts
Via Benzinga
Earnings Scheduled For February 25, 2025
Via Benzinga
4 Analysts Have This To Say About Arcutis Biotherapeutics
Via Benzinga
Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
How does ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) stack up against Mark Minervini’s strategy?
Via Chartmill
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Via Benzinga
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews
Via Benzinga
What's Going On With Arcutis Biotherapeutics Stock Monday?
Via Benzinga
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
Via Stocktwits
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
Via Investor's Business Daily
Exposures Product Safety
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Via Benzinga
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.